Oura's confidential SEC filing in May 2026, following its $900 million Series E round at an $11 billion valuation, anchors trader sentiment around post-IPO market caps near or above that level. Rapid revenue scaling—from roughly $500 million in 2024 to $1 billion in 2025, with management targeting close to $2 billion in 2026—supports expectations for multiples in the 6-10x forward sales range, typical for high-growth health tech. Closely bunched probabilities across $7.5 billion to $20 billion-plus brackets reflect uncertainty over final IPO timing, equity market conditions, and any dilution or comparable valuations from other 2026 listings. Key catalysts ahead include progress toward a public S-1 and updated 2026 financial results that could shift implied pricing.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$12.5B–$15B 17%
$20B+ 16%
$10B–$12.5B 15%
$17.5B–$20B 15%
$150,474 Vol.
$150,474 Vol.
<$7.5B
12%
$7.5B–$10B
13%
$10B–$12.5B
15%
$12.5B–$15B
17%
$15B–$17.5B
13%
$17.5B–$20B
15%
$20B+
16%
No IPO before January 2027
3%
$12.5B–$15B 17%
$20B+ 16%
$10B–$12.5B 15%
$17.5B–$20B 15%
$150,474 Vol.
$150,474 Vol.
<$7.5B
12%
$7.5B–$10B
13%
$10B–$12.5B
15%
$12.5B–$15B
17%
$15B–$17.5B
13%
$17.5B–$20B
15%
$20B+
16%
No IPO before January 2027
3%
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Market Opened: May 26, 2026, 12:28 PM ET
Resolver
0x69c47De9D...If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Resolver
0x69c47De9D...Oura's confidential SEC filing in May 2026, following its $900 million Series E round at an $11 billion valuation, anchors trader sentiment around post-IPO market caps near or above that level. Rapid revenue scaling—from roughly $500 million in 2024 to $1 billion in 2025, with management targeting close to $2 billion in 2026—supports expectations for multiples in the 6-10x forward sales range, typical for high-growth health tech. Closely bunched probabilities across $7.5 billion to $20 billion-plus brackets reflect uncertainty over final IPO timing, equity market conditions, and any dilution or comparable valuations from other 2026 listings. Key catalysts ahead include progress toward a public S-1 and updated 2026 financial results that could shift implied pricing.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated


Beware of external links.
Beware of external links.
Frequently Asked Questions